Evidence map›Paper›PMID 30954940›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019

Olayinka A Abiodun-Ojo, Akinyemi A Akintayo, Oladunni O Akin-Akintayo, Funmilayo I Tade, Peter T Nieh, Viraj A Master, Mehrdad Alemozaffar, Adeboye O Osunkoya, Mark M Goodman, Baowei Fei and 1 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. The Diagnostic Role ofFrontiers in oncology · 2021
    Pooled it
  2. Assessing the effectiveness of MRI,Polish journal of radiology · 2024
    Article
  3. Review
  4. Understanding and ImprovingProstate cancer · 2020
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Olayinka A Abiodun-OjoDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
Akinyemi A AkintayoDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
Oladunni O Akin-AkintayoDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
Funmilayo I TadeDepartment of Radiology, Loyola University Medical Center, Maywood, Illinois.
Peter T NiehDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia.
Viraj A MasterDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia.
Mehrdad AlemozaffarDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia.
Adeboye O OsunkoyaDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia.
Mark M GoodmanDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
Baowei FeiDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia dschust@emory.edu.
Emory University · USLoyola University Medical Center · USSouthwestern Medical Center · US

Funding

ACADEMIC-INDUSTRIAL PARTNERSHIP FOR TRANSLATION OF PET/TRUS GUIDED INTERVENTIONR01CA204254 · NCI · UNIVERSITY OF TEXAS DALLAS · PI FEI, BAOWEI · 2017 to 2021
$2.0M
MOLECULAR IMAGING DIRECTED, 3D ULTRASOUND-GUIDED, BIOPSY SYSTEMR01CA156775 · NCI · UNIVERSITY OF TEXAS DALLAS · PI FEI, BAOWEI · 2011 to 2016
$1.7M
Targeted fusion biopsy using anti-[18F]FACBC PET/CT and real-time 3D ultrasound gR21CA176684 · NCI · EMORY UNIVERSITY · PI FEI, BAOWEI, MASTER, VIRAJ · 2013 to 2014
$568k
NCI NIH HHS R01 CA156775NCI NIH HHS R01 CA204254NCI NIH HHS R21 CA176684
6 · The paper itself

Abstract

We evaluated

Indexed as

Carboxylic AcidsCyclobutanesPositron Emission Tomography Computed TomographyAgedBiological TransportBiopsyHumansMaleProstateProstatic NeoplasmsRecurrenceROC CurveCarboxylic AcidsCyclobutanesfluciclovine F-1818F-fluciclovineprostaterecurrencetargeted biopsy

Identifiers

PMID30954940
PMCPMC6836857
OpenAlexW2934881734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.